

# Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events

NCT06863480

---

Status	RECRUITING
Phase	Phase 1
Sponsor	University of Florida
Enrollment	30 participants

## Key Eligibility Criteria

---

### Inclusion (11)

- Adult patients (aged ≥18 years) with Hunt Hess Grade 1-3, Fisher score 3 or 3 and 4, aneurysmal subarachnoid hemorrhage within 24 hours of symptom onset (ruptured aneurysm confirmed by CTA, MRA or DSA)
- Must have external ventricular drain or lumbar drain, or plan to place an external ventricular drain or lumbar drain.
- Female subjects of child-bearing potential must have negative pregnancy test
- Signed informed consent from subject or legally authorized representative
- Able and willing to comply with followup visits
- ... and 6 more (see full listing online)

### Exclusion (36)

- Evidence for vasospasm or DCI prior to study enrollment
- Hemodynamically unstable pre-enrollment
- Severe or unstable concomitant condition or disease (e.g., known significant neurological deficit, cancer, hematologic or coronary disease), or chronic condition (e.g., liver disease, kidney disease, or psychiatric disorder), that may increase the risk associated with study participation, or may interfere with the interpretation of study results
- Subjects who have received an investigational product or participated in another interventional clinical study within 30 days prior to enrollment.
- Known hypersensitivity or severe allergic reaction to tocilizumab and/or other biologics agents (i.e. shock, anaphylactic reactions)
- ... and 31 more (see full listing online)

## Locations (1 total)

---

University of Florida Health (UF Health), Gainesville, Florida, United States